Ordinary shares, nominal value $0.0001 per share
- Symbol
- JAZZ
- Exchange
- NASDAQ
- Classification
- COMMON
- Status
- Current
Current Report · Items 8.01 · 8-K
Jazz Pharmaceuticals plc
JAZZNASDAQEQUITYCurrent
Other Events
Item 8.01. Other Events. On August 25, 2026, Jazz Pharmaceuticals plc (the “Company”) issued a press release announcing that the U.S. Food and Drug Administration approved two Ziihera® (zanidatamab-hrii)-containing regimens for the first-line treatment of adults with unresectable locally advanced or metastatic HER2-positive (HER2+) gastroesophageal adenocarcinoma (GEA):…
Company context
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) is a global biopharma company whose purpose is to innovate to transform the lives of patients and their families. We are dedicated to developing life-changing medicines for people with rare diseases - often with limited or no therapeutic options. We have a diverse portfolio of medicines, including leading therapies addressing epilepsies, cancers and sleep disorders. Our patient-focused and science-driven approach powers pioneering research and development advancements across our robust pipeline of innovative therapeutics. Jazz is headquartered in Dublin, Ireland with research and development laboratories, manufacturing facilities and employees in multiple countries committed to serving patients worldwide.
Current securities
Recent company filings
- Results of Operations and Financial ConditionOct 26, 2026
- Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory ArrangementsOct 9, 2026
- 4 filingOct 5, 2026
- 144 filingOct 1, 2026
- Entry into a Material Definitive Agreement · Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet ArrangementSep 23, 2026
Registered securities in this filing
Jazz Pharmaceuticals plc · 8-K · Filed 2026-08-25
Disclosure sections
Item 8.01Item 8.01 - Other Events
Item 8.01. Other Events.
On August 25, 2026, Jazz Pharmaceuticals plc (the “Company”) issued a press release announcing that the U.S. Food and Drug Administration approved two Ziihera® (zanidatamab-hrii)-containing regimens for the first-line treatment of adults with unresectable locally advanced or metastatic HER2-positive (HER2+) gastroesophageal adenocarcinoma (GEA): Ziihera plus Tevimbra® (tislelizumab-jsgr) and chemotherapy (HER2+ IHC 3+ or IHC 2+/ISH+), and Ziihera plus chemotherapy (HER2+ IHC 3+).
A copy of the press release is filed herewith as Exhibit 99.1 and incorporated herein by reference.